-
公开(公告)号：WO2022153195A1
公开(公告)日：2022-07-21
申请号：PCT/IB2022/050220
申请日：2022-01-13
Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER , TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE
Inventor： POIRIER, John T. , RUDIN, Charles , LEWIS, Jason , KHAN, Abdul , ANDREW, David , CHEN, Xinlei , LORENZ, Ivo , MATSUNAGA, Hironori
Abstract: It is an object of the present invention to provide an antibody-drug conjugate of an antibody binding to DLL3 and a drug having antitumor activity, a pharmaceutical composition comprising the antibody-drug conjugate and havoing therapeutic effects on a tumor, a method for treating a tumor using the antibody-drug conjugate or the pharmaceutical composition, and the like. The present invention provides an antibody-drug conjugate of an antibody binding to DLL3 and a drug having antitumor activity, a pharmaceutical composition comprising the antibody or the antibody-drug conjugate, and a method for treating a tumor.
-
公开(公告)号：WO2016164578A1
公开(公告)日：2016-10-13
申请号：PCT/US2016/026434
申请日：2016-04-07
Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER , CORNELL UNIVERSITY
Inventor： YOO, Barney , QUINN, Tom , BRADBURY, Michelle , WIESNER, Ulrich , LEWIS, Jason , MA, Kai , CHEN, Feng
CPC classification number: A61K47/6923 , A61K45/06 , A61K49/0058 , A61K49/1824 , A61K51/0478 , A61K51/10 , A61K51/1093 , A61K51/1251 , C07K16/40 , C07K2317/55 , C07K2317/569 , C07K2317/622
Abstract: Disclosed herein are nanoparticle immunoconjugates useful for therapeutics and/or diagnostics. The immunoconjugates have diameter (e.g., average diameter) no greater than 20 nanometers (e.g., as measured by dynamic light scattering (DLS) in aqueous solution, e.g., saline solution). In certain embodiments, the conjugates are silica-based nanoparticles with single chain antibody fragments attached thereto.
Abstract translation: 本文公开了可用于治疗和/或诊断的纳米颗粒免疫缀合物。 免疫缀合物具有不大于20纳米的直径（例如，平均直径）（例如，通过在水溶液例如盐水溶液中的动态光散射（DLS）测量）。 在某些实施方案中，缀合物是与其连接的单链抗体片段的二氧化硅基纳米颗粒。
-
公开(公告)号：WO2023034566A1
公开(公告)日：2023-03-09
申请号：PCT/US2022/042451
申请日：2022-09-02
Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER , SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES , TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC.
Inventor： POIRIER, John, T. , RUDIN, Charles , LEWIS, Jason , KHAN, Abdul , ANDREW, David , CHEN, Xinlei , LORENZ, Ivo, C. , TULLY, Kathryn, M. , TENDLER, Salomon
IPC: C07K16/18 , A61K39/395 , C07K14/47
Abstract: The presently disclosed subject matter provides antibodies or antigen-binding fragments thereof that bind to DLL3 and methods of using such antibodies or antigen-binding fragments thereof same.
-
公开(公告)号：WO2020150679A1
公开(公告)日：2020-07-23
申请号：PCT/US2020/014212
申请日：2020-01-17
Inventor： DE SOUZA FRANCA, Paula Demetrio , GONZALES, Junior , LEWIS, Jason , REINER, Thomas , KING, Glenn F.
Abstract: The present technology is directed to fluorophore-containing compounds useful in the imaging of peripheral neurons as well as to proteins useful in the treatment (including management) of pain.
-
公开(公告)号：WO2018232188A1
公开(公告)日：2018-12-20
申请号：PCT/US2018/037645
申请日：2018-06-14
Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
Inventor： CHEUNG, Nai-Kong , XU, Hong , SUZUKI-NISHIJIMA, Maya , NEMIEBOKA, Brandon , LEWIS, Jason
IPC: A61K39/00 , C07K14/705 , C07K16/28
Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to and neutralize the activity of L1-CAM protein. The antibodies of the present technology are useful in methods for detecting and treating a L1-CAM-positive cancer in a subject in need thereof.
-
Patent Agency Ranking6.发明申请RADIOLIGANDS FOR PRETARGETED PET IMAGING AND METHODS OF THEIR THERAPEUTIC USE 审中-公开用于预处理PET成像的放射性物质及其治疗方法
公开(公告)号：WO2016182804A1
公开(公告)日：2016-11-17
申请号：PCT/US2016/030657
申请日：2016-05-04
Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
Inventor： ZEGLIS, Brian , LEWIS, Jason , REINER, Thomas , HOUGHTON, Jacob Lee , MEYER, Jan-Philip , BRAND, Christian
CPC classification number: A61K51/0482 , A61K47/6897 , A61K51/0453
Abstract: Described herein are Tz/TCO-based pretargeting strategies using an Al[ 18 F]-NOTA-labeled tetrazine radioligand. This imaging strategy enables delineation of cancer at earlier time points compared to other imaging strategies and further decreases the radiation dose to healthy tissues compared to directly labeled antibodies. Al-based 18 F imaging of small molecules, such as tetrazine, has not been previously achieved due to the decomposition of tetrazine during radiofluorination. Radiofluorination is advantageous over other radiolabeling methods because, in addition to having a shorter half-life, 18 F is more readily available to produce and therefore integrated into hospital workflows.
Abstract translation: 本文描述了使用Al [18 F] -NOTA-标记的四嗪放射性配体的基于Tz / TCO的预靶向策略。 与其他成像策略相比，该成像策略能够在较早的时间点描绘癌症，并且与直接标记的抗体相比，进一步降低对健康组织的辐射剂量。 由于在放射性氟化期间四嗪的分解，以前尚未实现基于Al的18F小分子如四嗪的成像。 放射性氟化优于其他放射性标记方法，因为除了具有较短的半衰期之外，18F更容易获得生产，因此被整合到医院工作流程中。
-
7.发明申请
公开(公告)号：WO2023034557A1
公开(公告)日：2023-03-09
申请号：PCT/US2022/042436
申请日：2022-09-02
Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER , SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH , MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES , TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC.
Inventor： POIRIER, John, T. , RUDIN, Charles , LEWIS, Jason , KHAN, Abdul , ANDREW, David , CHEN, Xinlei , LORENZ, Ivo, C. , TULLY, Kathryn, M. , TENDLER, Salomon
IPC: C07K16/28 , C07K14/705 , C12N15/63
Abstract: The presently disclosed subject matter provides compositions and methods for in vivo diagnosis and treatment of diseases or disorders associated with DLL3. In particular, the presently disclosed subject matter provides novel anti-DLL3 antibodies-TCO conjugates, which can form a radioimmunoconjugate with a radioligand comprising a radioactive isotope.
-
公开(公告)号：WO2022153194A1
公开(公告)日：2022-07-21
申请号：PCT/IB2022/050219
申请日：2022-01-13
Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER , TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE
Inventor： POIRIER, John T. , RUDIN, Charles , LEWIS, Jason , KHAN, Abdul , ANDREW, David , CHEN, Xinlei , LORENZ, Ivo , MATSUNAGA, Hironori
Abstract: The present invention provides a novel anti-DLL3 antibody-pyrrolodiazepine derivative and a novel anti-DLL3 antibody-pyrrolodiazepine derivative conjugate using the same.
-
公开(公告)号：WO2021007371A1
公开(公告)日：2021-01-14
申请号：PCT/US2020/041282
申请日：2020-07-08
Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER , TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE
Inventor： POIRIER, John, T. , RUDIN, Charles , LEWIS, Jason , KHAN, Abdul , ANDREW, David , CHEN, Xinlei , LORENZ, Ivo
Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to delta-like protein 3 (DLL3). The antibodies of the present technology are useful in methods for detecting and treating a DLL3 -associated cancer in a subject in need thereof.
-
10.发明申请FREE PSA ANTIBODIES AS DIAGNOSTICS, PROGNOSTICS AND THERAPEUTICS FOR PROSTATE CANCER 审中-公开免费PSA抗体作为诊断，预防和治疗前列腺癌
公开(公告)号：WO2013063312A1
公开(公告)日：2013-05-02
申请号：PCT/US2012/061982
申请日：2012-10-25
Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
Inventor： SAWYERS, Charles , ULMERT, David , LEWIS, Jason , EVANS, Michael , LIJA, Hans
CPC classification number: A61K51/1018 , A61B5/4381 , A61B5/4833 , A61K51/1072 , G01N33/57434 , G01N2800/52
Abstract: The present invention provides methods of monitoring and measuring tumor- associated free PSA ("fPSA") with antibody polypeptides as an indication of androgen receptor signaling. In a particular embodiment, the methods may be used to assess the efficacy of anti-androgen and/or general anti-cancer treatments. The present invention also provides various methods and compositions relating to antibodies that are specific for tumor- associated or intratumoral fPSA. For example, the present invention provides compositions, including pharmaceutical compositions, comprising anti-fPSA antibodies, or fragments or characterisitic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using anti-fPSA antibodies and/or compositions.
Abstract translation: 本发明提供了用抗体多肽监测和测量肿瘤相关游离PSA（“fPSA”）作为雄激素受体信号传导的指征的方法。 在一个具体实施方案中，所述方法可用于评估抗雄激素和/或一般抗癌治疗的功效。 本发明还提供与针对肿瘤相关或肿瘤内fPSA特异的抗体相关的各种方法和组合物。 例如，本发明提供包含抗fPSA抗体或其片段或特征部分的组合物，包括药物组合物。 本发明还提供使用抗fPSA抗体和/或组合物的各种治疗和/或诊断方法。
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.016 seconds)
